<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> results from progressive pancreatic <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> caused by <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Activation of c-Jun <z:chebi fb="0" ids="29318,29339">NH2</z:chebi>-terminal kinase (JNK) inhibits insulin signaling in cultured cells and in vivo and thereby promotes <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Conversely, the peroxisome proliferator-activated receptor (PPAR) gamma synthetic ligands <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (TZDs) enhance insulin sensitivity </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we show that the TZDs <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="9753">troglitazone</z:chebi> inhibit <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha-induced JNK activation in 3T3-L1 adipocytes </plain></SENT>
<SENT sid="4" pm="."><plain>Our results indicate that PPARgamma mediates this inhibitory action because 1) it is reproduced by other chemically unrelated PPARgamma <z:chebi fb="4" ids="48705">agonist</z:chebi> ligands and blocked by PPARgamma <z:chebi fb="68" ids="48706">antagonists</z:chebi>; 2) it is enhanced by PPARgamma overexpression; and 3) it is abrogated by PPARgamma <z:chebi fb="40" ids="33697">RNA</z:chebi> interference </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, we show that <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> inhibits JNK activation and promotes the survival of pancreatic beta-cells exposed to interleukin-1beta </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo, the abnormally elevated JNK activity is inhibited in peripheral tissues by <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> in two distinct murine models of <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> fails to enhance insulin-induced <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in primary adipocytes from ob/ob JNK1-/- mice </plain></SENT>
<SENT sid="8" pm="."><plain>Accordingly, we demonstrate that the hypoglycemic action of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> is abrogated in the diet-induced <z:mp ids='MP_0001261'>obese</z:mp> JNK1-deficient mice </plain></SENT>
<SENT sid="9" pm="."><plain>In summary, we describe a novel mechanism based on targeting the JNK signaling pathway, which is involved in the hypoglycemic and potentially in the pancreatic beta-cell protective actions of TZDs/PPARgamma </plain></SENT>
</text></document>